Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Recruiting now · Phase 2
Conditions studied: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
In brief
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Key facts
- Study ID
- NCT05467891
- Run by
- Oana Danciu
- People needed
- 200
- Starts
- 2022-09-13
- Expected to finish
- 2029-08-15
- Last updated by the study team
- 2026-07-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Wisconsin — Madison, Wisconsin, United States (enrolling)
- University of Arizona — Phoenix, Arizona, United States (enrolling)
- Georgetown University — Washington D.C., District of Columbia, United States (enrolling)
- Virginia Commonwealth University — Richmond, Virginia, United States (enrolling)
- University of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)
- University of Illinois Cancer Center — Chicago, Illinois, United States (enrolling)
- Parkview Research Center — Fort Wayne, Indiana, United States (enrolling)
- University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States (enrolling)
- Tufts Medical Center — Boston, Massachusetts, United States (enrolling)
- University of Michigan Health System — Ann Arbor, Michigan, United States (enrolling)
- University of Nebraska Medical Center — Omaha, Nebraska, United States (enrolling)
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States (enrolling)
- University of New Mexico Comprehensive Cancer Center — Albuquerque, New Mexico, United States (enrolling)
- New York University Clinical Cancer Center — New York, New York, United States (enrolling)
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States (enrolling)
- Providence Portland Medical Center — Portland, Oregon, United States (enrolling)
- Penn State Cancer Institute — Hershey, Pennsylvania, United States (enrolling)
- Medical University of South Carolina — Charleston, South Carolina, United States (enrolling)
- University of Virginia Health System — Charlottesville, Virginia, United States (enrolling)
- Orlando Health Cancer Institute — Orlando, Florida, United States
- University of Michigan Health-West — Wyoming, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.